Andreas Knaack will be President of Invetech

Melbourne, Australia – Invetech, a leader in instrument development, custom automation and contract manufacturing, announced that Andreas Knaack has been named President of Invetech effective January 1, 2016. Colin White, Ph.D., who has served as president of Invetech since August 2012, has been named Global VP Advanced Staining at Leica Biosystems. Invetech and Leica are both operating companies owned by Danaher Corporation. White will continue to serve as President of Invetech until the end of 2015 to facilitate a smooth transition.

Knaack has more than 20 years of experience in the medical and diagnostics industry. He was formerly with Invetech from 2004 to 2012, where he held positions of increasing responsibility including Program Manager and Director of Biomedical Instruments and Devices. While at Invetech he had P&L responsibility for all of the company’s activities in design and development of scientific instruments and medical devices. He managed coordination of functions and teams from business development through service and product delivery, including support for many products that required compliance with FDA, QSR and other regulatory standards.

“I am very excited to be rejoining Invetech during an especially exciting time in the company’s history. On a global scale, the opportunities in all of the company’s key business platforms have never been stronger,” said Knaack, adding, “I look forward to working with the great team in place at Invetech to continue the momentum achieved under the leadership of Colin White in every area, including building our expertise, expanding our global presence and maximizing customer satisfaction from our full spectrum of services.”

From 2012 to 2015, Knaack transitioned to Leica Biosystems, where he was Global VP Core Histology. He earned his master’s degree in computer engineering at Hamburg University in Germany and began his career at Draeger Medical. He has also worked in venture capital, supporting and investing in early stage medical technology companies.

“In recent years, Invetech has significantly enhanced its reputation for innovation and quality, and now also has a very strong presence in the diagnostics and cell therapy markets, which continue to expand rapidly. As we work to build on these established strengths, I hope to apply my experience to help us target both new global markets and new industry sectors that represent important opportunities for us in the years ahead,” Knaack said.